跨美迪克斯医疗
TMDX
70.78
-5.74
-7.50%
跨美迪克斯医疗
US · TMDX
#2536 按市值排名
上市于 2019
70.78
-5.74
-7.50%
实时 - 追踪5344个代码 - 心跳于45秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例上升了0.2个百分点。
机构持股
- 机构持股比例
- 102.63% +0.24pp
- 机构数量
- 444 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund85.81%
Hedge Fund7.27%
Public Company5.59%
Individual/Insider3.19%
Private Company2.23%
Government Pension Fund1.07%
Insurance Company0.35%
Family Office/Trust0.18%
主要股东 截至 2026-06-30
BlackRock
16.14% · 5.60M 股
FMR
14.80% · 5.13M 股
Vanguard Portfolio Management, LLC
5.58% · 1.93M 股
Vanguard Capital Management, LLC
5.03% · 1.74M 股
State Street Global Advisors
4.10% · 1.42M 股
Macquarie Investment Management Business Trust
2.63% · 910.50K 股
Geode Capital Management, LLC
2.58% · 894.91K 股
UBS Asset Management
2.56% · 886.31K 股
Emerald Advisers, LLC
2.29% · 792.57K 股
Hood River Capital Management LLC
2.17% · 751.13K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 29次买入 · 20次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Waleed Hassanein | Chief Executive Officer | 1.63% |
| Edwin Kania | Independent Director | 0.89% |
| James Tobin | Independent Chairperson | 0.46% |
| Tamer Khayal | Chief Commercial Officer | 0.04% |
| Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | 0.04% |
| Thomas Gunderson | Independent Director | 0.04% |
| David Weill | Independent Director | 0.04% |
| Anil Ranganath | Senior Vice President | 0.01% |
| Merilee Raines | Independent Director | 0.01% |
| Gerardo Hernandez | Chief Financial Officer | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-10 | David Weill | Independent Director | Open Market Acquisition | +1,336 | $81.63 |
| 2026-08-16 | James Tobin | Independent Chairperson | Other Disposition | -18,000 | -- |
| 2026-07-09 | Waleed Hassanein | Chief Executive Officer | Other Acquisition | +49,669 | -- |
| 2026-07-09 | Waleed Hassanein | Chief Executive Officer | Other Derivative Acquisition | +112,984 | $71.23 |
| 2026-07-09 | Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | Other Acquisition | +11,727 | -- |
| 2026-07-09 | Nicholas Corcoran | Senior Vice President of Supply Chain & Operations | Other Derivative Acquisition | +17,784 | $71.23 |
| 2026-07-09 | Gerardo Hernandez | Chief Financial Officer | Other Acquisition | +17,246 | -- |
| 2026-07-09 | Gerardo Hernandez | Chief Financial Officer | Other Derivative Acquisition | +26,153 | $71.23 |
| 2026-06-14 | Thomas Gunderson | Independent Director | Derivative Exercise and Sale | -9,624 | $2.21–75.06 |
| 2026-06-14 | Thomas Gunderson | Independent Director | Derivative Exercise and Retained | +9,661 | $2.21 |
| 2026-05-19 | Edwin Kania | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | Merilee Raines | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | James Tobin | Independent Chairperson | Other Acquisition | +2,922 | -- |
| 2026-05-19 | Edward Basile | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | Stephanie Lovell | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | Thomas Gunderson | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-19 | David Weill | Independent Director | Other Acquisition | +2,922 | -- |
| 2026-05-18 | Matthew Forsyth | SVP, General Counsel & Corporate Secretary | Other Acquisition | +15,409 | -- |
| 2026-05-18 | Matthew Forsyth | SVP, General Counsel & Corporate Secretary | Other Derivative Acquisition | +23,171 | $66.13 |
| 2026-03-03 | Stephanie Lovell | Independent Director | Open Market Disposition | -1,193 | $149.62 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:33 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
跨美迪克斯医疗 讨论区 0 条评论